Read more

August 30, 2024
1 min read
Save

Phase 3 trials of pembrolizumab for lung cancer, skin cancer halted due to lack of efficacy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Two randomized phase 3 trials of pembrolizumab — one in lung cancer and one in skin cancer — have been discontinued due to lack of efficacy, according to the agent’s manufacturer.

Pembrolizumab (Keytruda, Merck) — an anti-PD-1 antibody — is approved for several oncology indications in the United States.

Older woman with skin cancer being examined by a doctor
Merck discontinued two trials of pembrolizumab, one for cutaneous squamous cell carcinoma and one for lung caner, due to lack of efficacy. Image: Adobe Stock

The KEYNOTE-867 trial had been designed to evaluate stereotactic body radiotherapy plus pembrolizumab or placebo for patients with stage I or stage II non-small cell lung cancer, including those who refused or were ineligible for surgery.

Merck discontinued the trial at the recommendation of an independent data monitoring committee. A prespecified interim analysis showed no improvement in EFS or OS — the trial’s primary endpoints — with pembrolizumab. Researchers also observed higher rates of adverse events, as well as adverse events that led to death, among patients assigned pembrolizumab vs. placebo.

The KEYNOTE-630 trial had been designed to compare pembrolizumab vs. placebo as adjuvant therapy for patients with high-risk locally advanced cutaneous squamous cell carcinoma who underwent surgery and radiation.

A pre-planned analysis showed no significant improvement in RFS — the study’s primary endpoint — with pembrolizumab. An independent data monitoring committee recommended the trial be stopped for futility.

Results of both trials will be shared with the scientific community, according to a Merck press release.